Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexbrompheniramine and Temozolomide in Recurrent High-Grade Glioma
NCT07859059Phase 2Not yet recruiting
- Sponsor
- University of Nebraska
- Start
- Jun 2027
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
A Phase 2 trial of dexbrompheniramine in glioma, glioblastoma (GBM), Gliosarcoma (GS), sponsored by University of Nebraska. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
dexbrompheniramine
03
Conditions
gliomaglioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT07859059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07859059.